Enrollment

CRIXIVAN®
(indinavir sulfate)
ISENTRESS®
(raltegravir)
GARDASIL®
[Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine]
JANUVIA®
(sitagliptin phosphate)
JANUMET®
(sitagliptin/metformin HCl)
MAXALT®
(rizatriptan benzoate)
SINGULAIR®
(montelukast sodium)
VARICELLA ZOSTER VIRUS-CONTAINING VACCINES


 

Merck & Co., Inc. is one of a number of pharmaceutical companies who participate in the Antiretroviral Pregnancy Registry, which is coordinated by Kendle International Inc. Since patients with HIV/AIDS are often placed on multiple-drug therapy, this cooperative registry collects, analyzes, and reports information on individual as well as combination drug regimens. To obtain an annual report from the Antiretroviral Pregnancy Registry or to obtain the forms to enroll a patient, click on the link below.

Thank You For Visiting Merck Pregnancy Registries

You are now leaving this site and connecting to:

The Antiretroviral Pregnancy Registry

Merck does not recommend the use of its products in any manner other than as described in the full product circular. Please review the full prescribing information before prescribing CRIXIVAN or ISENTRESS.

 

 

Package insert for CRIXIVAN
Patient package insert for CRIXIVAN
Package insert for ISENTRESS
Patient package insert for ISENTRESS

Or call 1-800-258-4263 to enroll a patient, report an outcome of pregnancy or request an annual report.

 

 


CRIXIVAN  |  GARDASIL  |  ISENTRESS  |  JANUVIA  |  JANUMET  |  MAXALT  |  PROQUAD  |  SINGULAIR  |  VARIVAX  |  ZOSTAVAX  |  Enrollment  |  Home  |  Privacy Policy

CRIXIVAN, GARDASIL, ISENTRESS, JANUVIA, JANUMET, MAXALT, PROQUAD, SINGULAIR, VARIVAX and ZOSTAVAX are registered trademarks of Merck & Co., Inc.

Copyright © 2006 Merck & Co., Inc. All rights reserved.
20651505(1)-06/06-EBS-PHY